Our News & Updates

Diagnostics, Press Releases

Diagnostic Partner 3a Receives BMBF Grant for Infectious Disease Screening Tests

Jun 10, 2020

Vancouver, Canada (June 10, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that its diagnostic...

Continue Reading

Drug Delivery, Press Releases

Parkinson’s Generic Transdermal Drug Delivery System

Jun 8, 2020

Vancouver, Canada (June 8, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that its wholly...

Continue Reading

Press Releases, Psychedelics

Exclusive Agreement with Oettinger Brewery for Cannabis-Infused Beverages signed

May 12, 2020

Vancouver, Canada (May 12, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that it has...

Continue Reading

Diagnostics, Press Releases

Infectious Disease Oral Dissolvable Biosensor Development

Apr 22, 2020

Vancouver, Canada (April 22, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that further to...

Continue Reading

Diagnostics, Press Releases

COVID-19 Screening Test, Oral Thin Film Biosensor Products and Identification Platform

Apr 20, 2020

Vancouver, Canada (April 20, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that it has...

Continue Reading

Press Releases

Exclusive Advisory Agreement for COVID-19 and Host Cell Interactions Signed

Mar 25, 2020

Vancouver, Canada (March 25, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY) (FSE:4XT) (OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that an exclusive infectious disease...

Continue Reading

Diagnostics, Press Releases

COVID-19 Test and Development Programs Update

Mar 20, 2020

Vancouver, Canada (March 20, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY) (FSE:4XT) (OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce updates to its infectious disease...

Continue Reading

Drug Delivery, Press Releases

Update on XPhyto’s Epilepsy Treatment Program

Mar 18, 2020

Vancouver, Canada (March 18, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce significant progress with respect to development...

Continue Reading

Diagnostics, Press Releases

XPhyto Initiates Infectious Disease Programs

Mar 3, 2020

Vancouver, Canada (March 03, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that its wholly owned German subsidiary,...

Continue Reading

Press Releases

Exclusive Strategic Partnership Commenced with Elite Bavarian Brewing & Beverage Institute Weihenstephan (TUM)

Feb 18, 2020

Vancouver, Canada (February 18, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that its wholly owned German subsidiary,...

Continue Reading

Press Releases

Three Year Strategic Supply, Import and Distribution Agreement with PharmaCielo Ltd. signed

Jan 27, 2020

Vancouver, Canada (January 27, 2020) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that the Company has signed a...

Continue Reading

Drug Delivery, Press Releases

XPhyto Therapeutics developing Epilepsy Treatment with Oral Thin Film Delivery System

Dec 6, 2019

Vancouver, Canada (December 6, 2019) - XPhyto Therapeutics Corp. (CSE:XPHY; FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that the development of Epilepsy treatment...

Continue Reading